HealthEquity (NASDAQ:HQY) EVP Michael Henry Fiore Sells 2,470 Shares of Stock

HealthEquity, Inc. (NASDAQ:HQY) EVP Michael Henry Fiore sold 2,470 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $95.00, for a total transaction of $234,650.00. Following the sale, the executive vice president owned 56,643 shares in the company, valued at approximately $5,381,085. This trade represents a 4.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Henry Fiore also recently made the following trade(s):

• On Friday, May 29th, Michael Henry Fiore sold 3,142 shares of HealthEquity stock. The stock was sold at an average price of $95.00, for a total transaction of $298,490.00.

HealthEquity Stock Up 0.4%

NASDAQ HQY traded up $0.41 during trading hours on Tuesday, reaching $96.98. 664,544 shares of the company’s stock traded hands, compared to its average volume of 1,014,519. HealthEquity, Inc. has a 52-week low of $72.76 and a 52-week high of $105.96. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.44 and a quick ratio of 3.44. The firm has a 50-day simple moving average of $86.41 and a 200 day simple moving average of $84.60. The firm has a market cap of $8.11 billion, a PE ratio of 36.32, a PEG ratio of 1.60 and a beta of 0.21.

HealthEquity (NASDAQ:HQY) last issued its quarterly earnings results on Thursday, May 28th. The company reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.13. The firm had revenue of $354.64 million for the quarter, compared to analysts’ expectations of $352.02 million. HealthEquity had a return on equity of 14.75% and a net margin of 17.25%.The firm’s quarterly revenue was up 7.2% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. Sell-side analysts anticipate that HealthEquity, Inc. will post 3.92 EPS for the current fiscal year.

Hedge Funds Weigh In On HealthEquity

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Wasatch Advisors LP grew its stake in shares of HealthEquity by 9.3% in the first quarter. Wasatch Advisors LP now owns 7,202,934 shares of the company’s stock worth $601,949,000 after acquiring an additional 613,288 shares during the period. Geode Capital Management LLC lifted its position in HealthEquity by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 2,201,232 shares of the company’s stock valued at $201,685,000 after purchasing an additional 5,671 shares during the period. Westfield Capital Management Co. LP lifted its position in HealthEquity by 13.7% during the fourth quarter. Westfield Capital Management Co. LP now owns 1,952,452 shares of the company’s stock valued at $178,864,000 after purchasing an additional 235,794 shares during the period. William Blair Investment Management LLC purchased a new stake in HealthEquity in the fourth quarter worth approximately $169,956,000. Finally, AQR Capital Management LLC boosted its holdings in HealthEquity by 59.3% in the third quarter. AQR Capital Management LLC now owns 1,764,268 shares of the company’s stock worth $167,200,000 after purchasing an additional 656,820 shares during the last quarter. Institutional investors own 99.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. reduced their price target on HealthEquity from $129.00 to $123.00 and set an “overweight” rating for the company in a report on Wednesday, March 18th. Wall Street Zen cut shares of HealthEquity from a “buy” rating to a “hold” rating in a research note on Saturday. BMO Capital Markets raised shares of HealthEquity from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $85.00 to $105.00 in a research report on Thursday, April 9th. Citigroup restated a “market outperform” rating on shares of HealthEquity in a research note on Monday, June 1st. Finally, Barrington Research reiterated an “outperform” rating and issued a $110.00 target price on shares of HealthEquity in a research note on Friday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $110.57.

HealthEquity Company Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.